This important paper presents updated guidelines that reflect the advances made in diagnosing and treating thyroid cancer since 1996. The American Thyroid Association reexamined the current strategies used to diagnose and treat thyroid nodules and differentiated thyroid cancer and developed new clinical guidelines based on principles of evidence-based medicine. The authors propose a surveillance guideline using thyroid-stimulating hormone (TSH)-stimulated serum thyroglobulin (Tg) levels for patients who have undergone total or near-total thyroidectomy and (131)I ablation for differentiated thyroid cancer and have no clinical evidence of residual tumor with a serum Tg below 1 µg/L during thyroid hormone suppression of TSH.
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This study shows that tumor amenable to early therapy may be found when recombinant human thyroid-stimulating hormone (rhTSH)-stimulated serum thyroglobulin (Tg) rises above 2 ng/mL without performing a diagnostic whole body scan, which provides only data concerning the completeness of thyroid ablation but not persistent tumor. An elevated rhTSH-stimulated Tg greater than 2 ng/mL warrants further study. These results provide the first direct evidence that thyroid-stimulating hormone (TSH) stimulates fluorine-18 fluorodeoxyglucose (FDG) uptake by differentiated thyroid carcinoma and that, therefore, FDG-PET is more accurate under recombinant human TSH than under suppression. These data indicate that benign thyroid lesions can be separated into distinct groups through molecular profiling. Analysis of the gene list may help further the understanding of thyroid tumorigenesis. Expression profiling may ultimately allow us to distinguish potentially malignant from benign follicular nodules. Intensity-modulated radiation therapy for nonanaplastic thyroid cancer is feasible and effective in appropriately selected cases. Acute toxicity is manageable with proactive clinical care. Ideal planning target volume doses have yet to be determined. Additional A retrospective review of a large number of cases of differentiated thyroid cancer was undertaken to analyze the effect of various risk groups on the extent of treatment and outcome. The author hypothesizes that risk groups are important in the long-term outcome of patients with differentiated thyroid cancer and that the management of well-differentiated thyroid cancer should be based on various prognostic factors and risk groups. Patients with undetectable or low thyroglobulin (Tg) concentrations and persistent occult disease can now be identified within the first year after initial treatment by recombinant human thyroid-stimulating hormone (rhTSH)-stimulated serum Tg concentrations greater than 2 µg/L, without performing new diagnostic body scans. These new follow-up paradigms promptly identify patients with lung metastases that are not evident on routine imaging but that respond to (131)I treatment. In addition, rhTSH can be given to prepare patients for (131)I remnant ablation or (131)I treatment for metastases, especially those who are unable to withstand hypothyroidism because of concurrent illness or advanced age or whose hypothyroid TSH fails to increase.
